Edition:
United States

Theradiag SA (ALTHE.PA)

ALTHE.PA on Paris Stock Exchange

2.37EUR
22 Jun 2017
Change (% chg)

€-0.02 (-0.84%)
Prev Close
€2.39
Open
€2.38
Day's High
€2.38
Day's Low
€2.33
Volume
15,566
Avg. Vol
39,361
52-wk High
€4.14
52-wk Low
€1.90

Latest Key Developments (Source: Significant Developments)

Theradiag announces free allocation of BSARs
Wednesday, 14 Jun 2017 02:00am EDT 

June 14 (Reuters) - THERADIAG SA :THERADIAG: FREE ALLOCATION OF REDEEMABLE STOCK WARRANTS FOR THE BENEFIT OF SHAREHOLDERS OF THE COMPANY.‍LAUNCH A REDEEMABLE STOCK WARRANT ("BSAR") FREE ALLOCATION PLAN FOR SHAREHOLDERS, AT RATE OF (1) WARRANT PER SHARE HELD WITH AN EXERCISE PRICE OF EUR 4​.  Full Article

Theradiag successful capital increase raising 4 million euros
Friday, 12 May 2017 02:07am EDT 

May 12 (Reuters) - THERADIAG SA ::SUCCESSFUL CAPITAL INCREASE, RAISING €4 MILLION.COMPANY HAS SOLD 1,749,563 NEW SHARES WITH PAR VALUE OF €1.70 EACH, AT A PRICE OF €2.30 EACH INCLUDING THE ISSUE PREMIUM, FOR A TOTAL AMOUNT OF €4,023,994.90 AND REPRESENTING 20.21% OF THE COMPANY'S POST-TRANSACTION CAPITAL.  Full Article

Theradiag announces the launch of a capital increase
Thursday, 11 May 2017 12:21pm EDT 

May 11 (Reuters) - THERADIAG SA ::ANNOUNCES THE LAUNCH OF A CAPITAL INCREASE.TRANSACTION WILL BE FOR A MAXIMUM AMOUNT OF €4 MILLION.NEW SHARES WILL RANK FOR DIVIDENDS IMMEDIATELY AND WILL BE ADMITTED TO TRADING ON ALTERNEXT PARIS.ISSUE PRICE TO BE AT LEAST EQUAL TO VOLUME-WEIGHTED AVERAGE PRICE IN FIVE TRADING SESSIONS BEFORE ISSUE PRICE IS SET, MINUS DISCOUNT OF UP TO 20%.FUNDS RAISED TO ENABLE THERADIAG TO FACILITATE AND STEP UP ITS INTERNATIONAL DEVELOPMENT, INCLUDING THE LAUNCH OF BIOCLIA® IN EUROPE.  Full Article

Theradiag Q1 revenue stable at 2.3 million euros
Thursday, 27 Apr 2017 02:00am EDT 

April 27 (Reuters) - Theradiag SA ::Q1 revenue 2.3 million euros ($2.5 million) versus eur 2.2 million year ago.  Full Article

Theradiag FY net loss narrows to eur 2.1 million euros
Wednesday, 1 Mar 2017 11:45am EST 

Theradiag SA : FY net loss of 2.1 million euros ($2.22 million) versus loss of 3.0 million euros year ago . FY operating loss of 2.2 million euros versus loss of 3.4 million euros year ago . FY revenue 9.0 million euros versus 7.6 million euros year ago .At December 31, 2016, Theradiag`s available net cash stood at 3.74 million euros , compared with 3.32 million euros at December 31, 2015..  Full Article

Theradiag 9 months revenue of 6.4 million euros, up 31%
Thursday, 13 Oct 2016 01:30am EDT 

Theradiag SA : 9 months revenue of 6.4 million euros ($7.2 million), up 31 pct .Q3 revenue of 1.7 million euros, up 20 pct.  Full Article

Lisa Tracker chosen to monitor patients treated with Remicade in the US
Monday, 5 Sep 2016 11:45am EDT 

Theradiag SA :Lisa Tracker chosen by Janssen Biotech for its program to monitor patients treated with Remicade in the US.  Full Article

Theradiag Q2 revenues rise 12 percent to 2.4 million euros
Tuesday, 5 Jul 2016 11:45am EDT 

Theradiag SA : Records for H1 a 36 percent increase in its consolidated revenues to EUR 4.6 million ($5.10 million) .Q2 revenues total EUR 2.4 million, up 12 percent on Q1 of 2016.  Full Article

Theradiag says Lisa tracker launched in the us market
Thursday, 16 Jun 2016 12:00pm EDT 

Theradiag SA : Lisa tracker launched in the us market .Four biotherapy monitoring tests being marketed by Miraca life sciences.  Full Article

Theradiag to present results at JFHOD congress
Tuesday, 15 Mar 2016 08:00pm EDT 

Theradiag SA:T present at JFHOD the results of a microRNA signature predicting a patient's therapeutic response in locally advanced rectal cancer.  Full Article

More From Around the Web

BRIEF-Theradiag announces free allocation of BSARs

* THERADIAG: FREE ALLOCATION OF REDEEMABLE STOCK WARRANTS FOR THE BENEFIT OF SHAREHOLDERS OF THE COMPANY